

CURRICULUM VITAE -- SASCHA DUBLIN

ADDRESS 1730 Minor Avenue, Suite 1600, Seattle, WA 98101-1448
Phone (206) 287-2870; fax (206) 287-2871
Email: Sascha.Dublin@kp.org

CURRENT AND PREVIOUS POSITIONS

Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute (formerly Group Health Research Institute), Seattle, WA, 10/2018-present
Associate Scientific Investigator (4/2013-10/2018) and Assistant Scientific Investigator (9/2007-4/2013), Kaiser Permanente Washington Health Research Institute, Seattle, WA
Affiliate Associate Professor (7/2014-present) and Affiliate Assistant Professor (1/2008-7/2014), Epidemiology Department, School of Public Health, University of Washington, Seattle, WA

EDUCATION AND TRAINING

A.B. Renaissance Studies, *magna cum laude*, Brown University, Providence, RI, 1992
M.D./Ph.D (in Epidemiology), University of Washington, Seattle, WA; Ph.D. 12/99, M.D 6/01
Residency, Internal Medicine, Oregon Health & Science University, Portland, OR (completed 6/04)
Fellow, Health Services Research & Development, VA Puget Sound, Seattle, WA (7/04-8/07)

HONORS AND AWARDS

1990 Kenneth Grief Prize for best essay on Shakespeare, Brown University, Providence, RI
1991 Phi Beta Kappa
1992 Thomas & Lydia Carpenter Premium, Brown University, Providence, RI
1994 Birch Award, American Medical Women's Assoc. - best research paper by a medical student
1997 Association of Women in Science Educational Foundation Citation of Merit
1997 Bertakis Award for Outstanding Oral Presentation, Western Student Medical Research Forum
1997 Student Workshop, Society for Epidemiologic Research, Edmonton, Canada
1997 New Investigators' Workshop, American Society for Preventive Oncology, New Orleans, LA
1997 Magnuson Scholar, University of Washington, Seattle, WA
1998 Achievement Rewards for College Scientists fellowship
1999 Lilienfeld Prize, Society for Epidemiologic Research - best research paper by graduate student
1999 Outstanding Student Award, Epidemiology Dept., University of Washington, Seattle, WA
2003 Alpha Omega Alpha medical honors society
2004 Humanitarianism award, Internal Medicine residency, OHSU
2004 Outstanding Teaching award, Internal Medicine residency, OHSU
2006 Summer Institute on Aging Research, National Institute on Aging, Wye River, MD
2007 Paul Beeson Career Development Award in Aging, National Institute on Aging
2008 Outstanding Reviewer, *Annals of Internal Medicine* (also named in 2009-2011, 2013, 2014, and 2016)
2009 Distinguished Reviewer, *Journal of General Internal Medicine*
2009 Selected for Young Investigators plenary session, HMO Research Network Annual Meeting
2010 Merck/American Geriatrics Society New Investigator Award
2010 Outstanding Poster Award, American Geriatrics Society Annual Meeting
2011 Early Career Investigator Award, HMO Research Network Annual Meeting
2011 Emerging Clinical Leaders program, Group Health, Seattle, WA
2012 Honorable Mention, Best Paper Award, *Pharmacoepidemiology and Drug Safety* (co-author)

- 2014 Invited faculty, Society for Epidemiologic Research Student Workshop, Seattle, WA
- 2014 Best paper award (co-author), Epidemiology Section, American Geriatrics Society Annual Scientific Meeting
- 2017 Best Paper Award, *Pharmacoepidemiology and Drug Safety* (co-author), for paper on oral diabetes drugs in combination with insulin and risk of myocardial infarction and stroke
- 2017 Honorable Mention, Best Paper Award, *Pharmacoepidemiology and Drug Safety* (co-author), for paper on exposure to sulfonamide antibiotics in pregnancy and risk of birth defects
- 2018 Honorable Mention, Best Paper Award, *Pharmacoepidemiology and Drug Safety* (co-author), for paper on opioid risk reduction initiatives and risk of motor vehicle collisions in patients on chronic opioid therapy
- 2018 Nominated for Outstanding Faculty Mentor Award, KP Washington Health Research Institute
- 2019 Editors' Choice Award, *Journal of the American Geriatric Society* (co-author), for a paper on dementia risk in relation to use of proton pump inhibitors
- 2019 Outstanding Reviewer, *Pharmacoepidemiology and Drug Safety* (also named in 2010, 2011, 2013 and 2015)
- 2019 Nominated for Outstanding Faculty Mentor Award, KP Washington Health Research Institute
- 2020 Federal Labs Consortium for Technology Transfer (FLC) Impact Award, for a project that developed a mobile app to collect information from patients about medication exposure and outcomes. *This award honors employees whose technology transfer efforts have made a tangible and lasting impact on the populace or marketplace ranging from a local to a global scale.* My role on this project was as a co-investigator and site Principal Investigator.

GRANTS AND CONTRACTS

ACTIVE

- None (PI: Brown) 10/1/2020-8/8/2022
 GlaxoSmithKline
 Title: GSK Pregnancy Exposure Study
 Major Goal: Using data from 6 healthcare systems or insurance providers nationwide, we will describe the use of certain biologic medications in women of childbearing age and pregnant women. We will also describe characteristics associated with exposure to these medications. These activities will lay the groundwork for future studies of pregnancy outcomes. Aims 2 and 3 focus on using electronic health records (EHR) data to obtain richer data about exposed women.
 Role: Co-Investigator (leading Aims 2 and 3) and Site Principal Investigator
 Direct costs: \$187,298 (at KPWHRI only)
- R01AG069734 (PIs: Dublin and Barnes) 9/18/2020-5/31/2025
 National Institute on Aging
 Title: Low-cost Detection of Dementia Using Electronic Health Records Data: Validation and Testing of the eRADAR Algorithm in a Pragmatic, Patient-Centered Trial
 Major Goal: To conduct a pragmatic clinical trial of targeted dementia screening in primary care. We will identify high-risk patients using a novel risk score, eRADAR, which draws on information from the electronic health record. We will carry out clinical trials at Kaiser Permanente Washington and UC San Francisco comparing targeted screening of high-risk individuals vs. usual care (no screening). Outcomes we will study are dementia diagnosis rates, healthcare utilization, and patient experience and satisfaction.
 Role: Multiple Principal Investigator
 Direct costs: \$2,552,795
- R01AG067427 (PIs: Dublin and Barnes) 7/15/2020-4/30/2024
 National Institute on Aging

Title: Identifying and Supporting Patients with Undiagnosed Dementia Using the EHR Risk of Alzheimer's and Dementia Assessment Rule (eRADAR): A Pilot Clinical Trial
Major Goal: To conduct a pilot randomized trial of targeted dementia screening in primary care. We will identify high-risk patients using a novel risk score, the electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR), which draws on information from the electronic health record. This study will randomize about 50 primary care providers and their 24,000 patients to receive targeted outreach vs. usual care. We will examine acceptability, feasibility, dementia diagnosis rates, and healthcare utilization, to lay the groundwork for a future full-scale clinical trial.
Role: Multiple Principal Investigator
Direct costs: \$1,992,997

None (PI: Dublin) 6/1/2020-5/31/2021

Garfield Memorial Fund

Title: Potential for Repurposing Currently Approved Medications to Fight COVID-19: A Proof-of-Concept Study

Major Goal: Using data from 3 Kaiser Permanente regions, to examine the use of various medications in relation to risk of acquiring infection with SARS-CoV-2, and 2) to examine illness severity associated with the use of these medications compared to non-use, including the outcomes of hospitalization, admission to the intensive care unit (ICU), and mortality.

Role: Principal Investigator

Direct costs: \$263,615

R24 AG064025 (PIs: Boyd and Steinman) 8/15/2019-7/31/2024

National Institute on Aging

Title: U.S. Deprescribing Research Network

Major goal: To develop and disseminate evidence about deprescribing for older adults, the structured process of stopping unnecessary or potentially harmful medications in a safe and effective way. The network will provide resources and supports to catalyze the expansion of deprescribing research and to promote collaboration and mutual learning.

Role: Co-lead, Data and Resources Core

U01 CE002967 (PI: Phelan) 9/30/2018-9/29/2022

Centers for Disease Control and Prevention

Title: Reducing CNS-active Medications to Prevent Falls and Injuries in Older Adults

Major Goals: To refine and test an intervention to reduce falls in older adults by reducing the use of central-nervous-system-active medications among older adults who receive medical care through Kaiser Permanente (KP) Washington.

Role: Co-Investigator

R01 AG057508 (PIs: Yaffe, Larson) 9/15/2017-4/30/2021

National Institute on Aging

Title: Multi-domain Alzheimer's Risk Reduction Study Pilot

Major Goals: To develop and then pilot test a unique personalized multiple risk factor reduction strategy for older people aiming to prevent dementia. This project will shape plans for a larger nationwide trial of multiple risk factor reduction to prevent dementia.

Role: Co-Investigator

Direct Costs (all sites): \$2,000,727

COMPLETED

None (PI: Dublin) 1/1/2020-12/31/2020

KP Washington Health Research Innovation Fund

Title: Building New Collaborations and Exploring New Data Sources to Study Pregnancy Outcomes
Major Goal: To explore and access new data sources to study medication safety in pregnancy, including New Zealand country-wide data on pregnancy exposures and outcomes and Washington State's All-Payer Claims Database.

Role: Principal Investigator

Direct costs: \$44,606

HHSF223201400042I (PI: Toh)

9/15/2016-9/14/2020

Food and Drug Administration

Title: Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP)

Major Goals: To maintain all data, data linkages, standardized datasets, and organizational structure created in the Medication Exposure in Pregnancy Risk Evaluation Program pilot program.

Role: Site Principal Investigator

Direct costs (KPWA only): \$36,590

R01 HD082141 (PI: Dublin)

9/5/2015-6/30/2020

National Institute of Child Health and Human Development

Title: Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment

Major Goals: 1) To evaluate the effect of treatment of mild to moderate hypertension in pregnancy, compared to no treatment, on maternal and infant outcomes; 2) to compare outcomes with different antihypertensive medications; and 3) to determine whether the benefits and risks vary by maternal race/ethnicity or obesity status.

Role: Principal Investigator

Direct costs: \$3,318,411

HHSF223201400042I (PI: Toh)

9/29/2016-12/31/2019

Food and Drug Administration

Title: Evaluation of the Risk of Neural Tube Defects Among Live Births Exposed to Maternal Prescription Opioids During Early Pregnancy

Major Goal: To measure the association between in utero exposure to prescription opioids during early pregnancy and neural tube defects.

Role: Co-Investigator

Direct costs (all sites): \$3,507,047

None (PI: Dublin)

1/1/2019-12/31/2019

KP Washington Health Research Institute Development Fund

Title: Exploring New Data Sources for Pregnancy Research

Major Goal: To explore and access new data sources to study medication safety in pregnancy, including New Zealand country-wide data on pregnancy exposures and outcomes and Washington State's All-Payer Claims Database.

Role: Principal Investigator

Direct costs: \$76,918

U01AG006781 (PIs: Larson and Crane)

5/15/2015-4/30/2020

National Institute on Aging

Title: Alzheimer's Disease Patient Registry

Major Goals: 1) to examine the independent and joint effects of multiple modifiable cardiovascular risk factors and their treatments on the aging brain and 2) to explore why some people retain functioning despite considerable physical and neuropathological comorbidity, examining predictors of resilience and robust aging.

Role: Co-Investigator

Direct costs: \$10,154,578

R56 AG056417 (PI: Barnes) 9/15/2017-9/14/2019
National Institute on Aging
Title: Development and Validation of the EMR Risk of Alzheimer's and Dementia Assessment Rule
Major Goals: To develop and validate the EMR Risk of Alzheimer's and Dementia Assessment Rule (eRADAR), an automated tool that will use information in the electronic medical record to identify patients likely to have current, undiagnosed dementia. We will conduct focus groups and interviews with patients, caregivers, clinicians and health care system leaders to learn how to best implement eRADAR in clinical practice.
Role: Site Principal Investigator; Co-Investigator
Direct costs (all sites): \$500,000

JA #32369 (PI: Hansen) 2/1/2018-7/31/2019
Jazz Pharmaceuticals
Title: Analysis of the Risk of Motor Vehicle Accidents in Patients with Obstructive Sleep Apnea
Major Goals: To examine the association between obstructive sleep apnea and motor vehicle collisions.
Role: Site Principal Investigator; Co-Investigator
Direct costs (KPWA only): \$214,771

R21AG055604 (PI: Scherrer) 4/15/2017-6/30/2019
National Institute on Aging
Title: A Big Data Research Study on the Relationship between Metformin Use and Dementia
Major Goal: To measure the association between use of metformin and risk of developing dementia using data from the Veteran's Health Administration and Kaiser Permanente Washington.
Role: Site Principal Investigator; Co-Investigator
Direct costs (KPWA only): \$98,940

None (PI: Dublin) 1/1/2016-12/31/2018
Group Health Foundation Partnership for Innovation
Title: Evaluating the Impact of the Gestational Diabetes Guideline Change at Group Health
Major Goal: To evaluate the impact on pregnancy outcomes of major changes to the Group Health guideline about screening and treatment for gestational diabetes. Outcomes to be studied include prevalence of gestational diabetes, cesarean delivery, labor induction, large for gestational age infant, macrosomia, neonatal intensive care unit stay, and neonatal hypoglycemia.
Role: Principal Investigator
Direct costs: \$330,332

HHSF223201000009I (PI: Adams) 10/1/2014-9/29/2018
Food and Drug Administration
Title: Retrospective Cohort Study of High Dose Proton Pump Inhibitor (HD-PPI) Use, Labeled PPI Use, or H2 Receptor Antagonist (H2RA) Use on Risk of Hip Fractures and a Nested Case-control Study of Cytochrome P4502C19 Pharmacogenetics
Major Goals: To study the association between use of high dose proton pump inhibitors and hip fracture, including pharmacogenomics.
Role: Co-Investigator
Direct costs (KPWA only): \$80,814

R01 HD071986 (PIs: Dublin and Getahun) 9/1/2013-5/31/2018
National Institute of Child Health and Human Development
Title: Elective Induction of Labor and Pregnancy Outcomes

Major Goals: 1) To examine maternal and infant outcomes associated with elective induction of labor compared to expectant management at 38, 39 and 40 weeks of gestation; and 2) to examine how risks vary according to maternal race/ethnicity, parity, and obesity status.

Role: Multiple Principal Investigator

Direct costs: \$2,613,463

HHSF223201400030I (PI: Platt)

9/1/2016-04/30/2018

Food and Drug Administration

Title: Collection of Patient-Provided Information through a Mobile Device Application to Support FDA Sentinel

Major Goal: To develop a generalizable approach for collecting patient-reported data via a mobile platform to support medical product safety surveillance. We will develop and pilot test a mobile app to capture data from pregnant women about medication exposures, pregnancy outcomes, and potential confounders that will be matched with Kaiser Permanente electronic health data.

Role: Co-Investigator, Site Principal Investigator

Direct costs (at KPWA): \$171,970

None (PI: Lapham)

1/1/2017-12/31/2017

Group Health Research Institute Development Fund

Title: Cannabis Use During Pregnancy: Pilot Quantitative and Qualitative Data

Major Goal: To conduct preliminary quantitative and qualitative pilot work to describe the prevalence of cannabis use, possible reasons for cannabis use, and pregnancy outcomes, among pregnant women within Kaiser Permanente Washington.

Role: Co-Investigator

R24AG045050 (PI: Gurwitz)

1/1/2016-12/31/2017

National Institute on Aging

Title: Electronic Medical Record (EMR) Predictors of Undiagnosed Dementia

Major Goals: To obtain pilot data to support future work to develop an automated risk score to identify patients who are likely to have undiagnosed dementia. We will explore novel EMR data suggesting chaotic patterns of care (e.g., missed clinic visits); describe patterns of health care utilization; and describe medication adherence in patients with undiagnosed dementia compared to patients without dementia.

Role: Principal Investigator of pilot project

Direct costs (at KPWA): \$25,000

IHS-1306-02198 (PI: Von Korff)

5/1/2014-4/30/2017

Patient-Centered Outcomes Research Institute

Title: Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks

Major Goals: To evaluate Group Health's chronic opioid therapy risk mitigation initiative to determine whether it reduced risks of prescription opioid use disorders and affected pain outcomes of chronic pain patients using opioids long-term. We will also assess effects of the risk mitigation initiative on major adverse health events including fractures, motor vehicle accidents, and opioid overdose.

Role: Co-investigator

None (PI: Barnes)

8/1/2015-12/31/2016

Tideswell Foundation

Title: Detection of Undiagnosed Dementia Through the Electronic Medical Record (EMR)

Major Goal: The aims of this pilot study are: 1) Within a prospective cohort study of incident dementia, to identify a cohort of patients whose dementia went unrecognized by their healthcare providers; and 2) to compare the characteristics of patients with unrecognized dementia to those of study participants without dementia.

Role: Co-Investigator

None (Dublin) 1/1/2016-8/31/2016

Group Health Research Institute Development Fund

Title: Pregnancy Perspectives: Hypertension in Pregnancy

Major Goal: To conduct focus groups of pregnant women and women who have given birth in the past 3 years who had hypertension during pregnancy to solicit their perspectives on interventions including which outcomes are most important, to help guide future research.

Role: Principal Investigator

Direct costs: \$49,974

None (Dublin) 3/1/2015-10/31/2015

Group Health Research Institute Development Fund

Title: Pregnancy Perspectives

Major Goal: To conduct focus groups of pregnant women and women who have given birth in the past 3 years to solicit their perspectives on interventions in pregnancy including treatment for diabetes, to help guide future research.

Role: Principal Investigator

Direct costs: \$39,979

HHSF223200510012C-COA7 (PI: Platt) 9/1/2014-9/30/2015

Food and Drug Administration

Title: Feasibility Assessment for a Claims-based Retrospective Case-Control Study of the Association between Opioid Use during Pregnancy and Neural Tube Defects Using Data from the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP)

Major Goal: To determine feasibility of conducting a case-control study of exposure to examine whether use of opioids in early pregnancy increases risk of birth defects in exposed infants.

Role: Site Principal Investigator

None (PI: Dublin) 8/1/2012-7/31/2015

Branta Foundation

Title: Medications and Dementia Risk in Older Adults

Major Goals: To study the association between 3 medication classes - opioid pain medications, benzodiazepines, and general anesthesia - and brain outcomes in older adults, including dementia, global cognitive trajectory, and neuropathology. The opioid analyses will 1) compare the impact of long versus short acting medications and 2) assess whether opioid effects differ in subgroups including by age, gender, and baseline cognitive function.

Role: Principal Investigator

Direct costs: \$360,285

HHSF223200910006I (PI: Platt) 12/18/2013-5/17/2015

Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: A Protocol-based Assessment of Selected Medications and Death

Major Goals: To develop and implement protocols to assess the associations of antibiotics and antidepressants with sudden cardiac death, including assessing the feasibility of linking the Mini-Sentinel Distributed Database with the National Death Index and establishing a process for this linkage.

Role: Co-Investigator

HHSF223200910006I (Platt) 1/1/2014-3/31/2015

Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: Analytical Methods to Assess the Robustness of Drug Safety Monitoring
Major Goals: To identify and implement sensitivity analyses that can be carried out within the Mini-Sentinel context to examine the potential impact on results of biases such as residual confounding, exposure, and outcome and covariate misclassification.
Role: Workgroup member

None (PI: Dublin) 1/1/2011-12/31/2014
Branta Foundation

Title: Pneumonia Risk Project
Major Goals: 1) To examine pneumonia risk in relation to use of angiotensin-converting enzyme inhibitors; 2) to compare different methods for studying medications and pneumonia risk, identifying and disseminating "best practices"; and 3) to develop a risk score for pneumonia based on simple and easily obtained measures.
Role: Principal Investigator
Direct costs: \$367,516

R03 AG042930 (PI: Dublin) 8/1/2012-7/31/2014
National Institute on Aging

Title: Opioids and the Aging Brain: Dementia, Cognitive Decline and Neuropathology
Major Goals: To examine whether long-term use of prescription opioids is associated with a) higher incidence of all-cause dementia or Alzheimer's disease; b) more rapid decline in global cognitive functioning, and c) higher burden of Alzheimer's disease neuropathology.
Role: Principal Investigator
Direct costs: \$100,000

HHSF223200910006I (PI: Platt) 5/8/2012-12/31/2013
Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: Birth Certificate Data Matching for the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) Program
Major Goals: To expand the data available for post-marketing vaccine safety surveillance by investigating and supporting matching of health plan data to state birth certificate and fetal death certificate data for Mini-Sentinel Data Partners.
Role: Co-Investigator

HHSF223200910006I (PI: Platt) 9/1/2012-10/31/2013
Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: Using Supplemental Information for Improved Confounder Adjustment
Major Goals: 1) To develop a 2-phase sampling design strategy for supplemental data collection (e.g. medical record review) to refine a signal detected in automated data; 2) To develop a framework to determine which confounders should be collected; and 3) To develop an alternative strategy through which supplemental information could be collected on an ongoing basis, before a signal is detected.
Role: Workgroup Lead

HHSF22301008T (PI: Platt) 9/12/2012-9/11/2013
Food and Drug Administration

Title: Feasibility Assessment for Retrospective Cohort Study of Risk of Hip Fractures Associated with High Dose, Long Term Proton Pump Inhibitor (PPI) Use or H2 Receptor Antagonists (H2RA) and Cytochrome P450 Pharmacogenomics

Major Goals: 1) To create and describe a cohort of new users of prescription PPI or H2RA, including a nonuser comparison group, including evidence of ability to link patient records to biospecimens; and 2) to develop innovative strategies to address confounding by indication and analyze pharmacogenetic influences of CYP2C19 inhibition.

Role: Co-Investigator

K23 AG028954 (PI: Dublin)

9/15/2007-8/31/2013

National Institute on Aging

Title: Pharmacoepidemiology in the elderly: medications, pneumonia risk and confounding. Paul Beeson Career Development Award in Aging.

Major Goals: To develop a career as an independent physician-investigator studying medication safety in older adults; to provide new knowledge about medications and risk of pneumonia in older adults; and to contribute to improved research methods in studies of medication safety in older adults.

Role: Principal Investigator

Direct costs: \$800,000

HHSF223200510012C-COA7 (PI: Platt)

9/14/2011-8/31/2013

Food and Drug Administration

Title: Systemic Sulfonamide Use During Pregnancy and the Risk of Selected Congenital Abnormalities in the Offspring

Major Goals: 1) To measure the association between exposure to sulfonamides during pregnancy and congenital abnormalities in the offspring. 2) To maintain all data, data linkages, standardized datasets, and organizational structure created in the Medication Exposure in Pregnancy Risk Evaluation Program pilot program.

Role: Site Principal Investigator

Direct costs (all site): \$1,419,830

None (PI: Dublin)

1/1/2010-12/31/2012

Group Health Research Institute Development Fund

Title: Natural Language Processing to Identify Pneumonia from Radiology Reports

Major Goal: To validate Natural Language Processing tools to identify pneumonia cases from electronic radiology text reports and to assess these tools' transferability to other health care systems.

Role: Principal Investigator

HHSF223200510012C-COA7 (PI: Platt)

10/1/2010-9/30/2011

Food and Drug Administration

HMORN CERT Epidemiological Studies of the Adverse Effects of Marketed Drugs: Prescribing in Pregnancy

Major Goals: This project builds on previous work creating a multisite data repository for studies of birth outcomes. The specific objectives are: 1) to evaluate gestational age assumptions based upon administrative health plan data compared to birth certificate data, and 2) to describe the prevalence and patterns of use of antidiabetic medications during pregnancy.

Role: Site Principal Investigator

HHSF223200910006I (Platt)

4/1/2010-7/31/2011

Food and Drug Administration

Title: Efforts to Develop the Sentinel Initiative: Review of the Evidence for Selected Health Outcomes of Interest (HOIs): Atrial Fibrillation

Major Goals: To review the literature to identify algorithms that have been examined to identify atrial fibrillation using electronic health data, summarize the test characteristics of those algorithms, and identify areas for future research.

Role: Principal Investigator

P30 AG0345592 (PI: Teri) 9/30/2009-8/31/2011
National Institutes of Health
Title: Cognitive Function and Breast Cancer Care – Roybal Center
Major Goals: To investigate how often cognitive and functional status are assessed prior to treatment for breast cancer and to determine how these characteristics influence treatment decisions.
Role: Co-Investigator on this Roybal Center pilot project

HHSF223200510012C (Platt) 10/4/2010-7/31/2011
Food and Drug Administration
Title: Center for Drug Evaluation and Research Antiepileptic Study
Major Goals: This project will build on work started during Year 2 of CERT III where the process for multisite active surveillance for medication safety was developed and tested. We will develop additional methods to understand and overcome potential biases that arise during active drug safety surveillance. This work will focus on the brand-to-generic transition of several antiepileptic medications.
Role: Site Principal Investigator

U18 HS016955 (PI: Platt) 9/1/2007-8/31/2011
Agency for Healthcare Research and Quality
Title: HMO Research Network Center for Education and Research on Therapeutics III: Infrastructure
Major Goals: To continue studies on drug safety and pharmacovigilance in a population-based setting. The Year 4 pilot project led by Dr. Dublin has the following aims: 1) to describe labor induction trends across 10 health plans from 2001-2007, including induction without a documented indication; 2) to describe characteristics of women undergoing elective induction compared to medically indicated induction or no induction; and 3) to validate the algorithm for elective induction through medical record review.
Role: Lead Investigator for Year 4 project; Site Principal Investigator in all years

HHSF223200510012C-COA7 (Platt) 8/18/2008-9/22/2010
Food and Drug Administration
Title: HMORN CERT Epidemiological Studies of the Adverse Effects of Marketed Drugs: Prescribing in Pregnancy
Major Goals: This multisite collaborative project will develop infrastructure to enable the ongoing study of medication use and outcomes in pregnancy. Specific components include: 1) maternal-infant record linkage; 2) linkage to infants' birth certificate data; 3) validation of data elements through medical chart abstractions; and 4) annual update of the datasets.
Role: Site Principal Investigator, Group Health

5 U18 HS016955 (PI: Platt) 9/1/2008-8/31/2010
Agency for Healthcare Research and Quality
Title: HMO Research Network CERT III – Adverse Drug Reactions
Major Goals: Aim 1) to pilot test prospective surveillance, using sequential testing methodologies, for identifying serious adverse drug reactions (ADRs) to newly marketed drugs. This project will examine safety of new generic antiepileptic drugs compared to the equivalent branded medications. Aim 2) To develop a new mixed structure model data mining method.
Role: Site Principal Investigator, Group Health

HHSF223200510010C (PI: Platt) 7/1/2008-6/30/2009
Food and Drug Administration
Title: HMORN CERT Epidemiological Studies of the Adverse Effects of Marketed Drugs: ADHD and Cardiovascular Outcomes: Medical Record Review

Major Goals: To validate data elements from the ADHD Phase I study by reviewing charts of patients suffering ischemic or hemorrhagic stroke.

Role: Site Principal Investigator, Group Health

HHS290200500331-TO4-WA1 (PI: Platt)

9/1/2007-2/28/2009

Agency for Healthcare Research and Quality

Title: A Multicenter, Observational Cohort Study To Assess the Cardiovascular Risks of Medications Prescribed for Attention Deficit Hyperactivity Disorder

Major Goals: To examine the risks of serious cardiovascular events including stroke, sudden cardiac death, and myocardial infarction in children and adults receiving medications for ADHD.

Role: Site Principal Investigator, Group Health

Ovarian Cancer and Prescription Drug Use. University of WA Royalty Research Fund. Project director (dissertation project; P.I. Dr. Noel Weiss). August 1997-July 1998.

Johnson & Johnson/Woodrow Wilson Foundation Dissertation Grant in Women's Health, 1997.

PEER-REVIEWED ARTICLES

1. **Dublin S**, Rosenberg P, Goedert JJ. Patterns and predictors of high-risk sexual behavior in female partners of HIV-infected men with hemophilia. *AIDS*, 1992 May;6(5):475-82. doi: 10.1097/00002030-199205000-00006.
2. Goedert JJ, **Dublin S**. Perinatal transmission of HIV type 1: associations with maternal anti-HIV serological reactivity. *AIDS Res and Hum Retroviruses*, 1994 Sep;10(9):1125-34. doi: 10.1089/aid.1994.10.1125.
3. **Dublin S**, Riccardi V, Stephens K. Methods for rapid detection of a recurrent nonsense mutation and documentation of phenotypic features in neurofibromatosis type 1 patients. *Hum Mutat*, 1995;5(1):81-5. doi: 10.1002/humu.1380050111
4. Weiss NS, **Dublin S**. Accounting for time-dependent covariates whose levels are influenced by exposure status. *Epidemiology*, 1998 Jul;9(4):436-40.
5. **Dublin S**, Lydon-Rochelle M, Kaplan R, Watts DH, Critchlow CW. Maternal and neonatal outcomes after induction of labor without an identified indication. *Am J Obstet Gynecol*, 2000 Oct;183(4):986-94. doi: 10.1067/mob.2000.106748
6. **Dublin S**, Rossing MA, Heckbert SR, Goff BA, Weiss NS. Risk of ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally-acting medications. *Cancer Causes Control*, 2002 Feb;13(1):35-45.
7. Velicer CM, **Dublin S**, White E. Cimetidine use and the risk of prostate cancer: results from the VITAL cohort study. *Ann Epidemiol*, 2006 Dec;16(12):895-900. Doi: 10.1016/j.annepidem.2006.03.003
8. Velicer CM, **Dublin S**, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. *Prostate Cancer Prostatic Dis*, 2007;10(1):46-51. doi: 10.1038/sj.pcan.4500914.
9. **Dublin S**, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, Smith NL, Heckbert SR. Risk of new-onset atrial fibrillation in relation to body mass index. *Arch Intern Med*, 2006 Nov 27;166(21):2322-8. doi: 10.1001/archinte.166.21.2322.
10. Glazer NL, **Dublin S**, Smith NL, French B, Jackson LA, Hrachovec JB, Siscovick DS, Psaty BM, Heckbert SR. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. *Arch Intern Med*, 2007 Feb 12;167(3):246-52. doi: 10.1001/archinte.167.3.246.
11. Lovasi GS, Lemaitre RN, Siscovick DS, **Dublin S**, Bis JC, Lumley T, Heckbert SR, Smith NL, Psaty BM. Amount of leisure-time physical activity and risk of nonfatal myocardial infarction. *Ann Epidemiol*, 2007 Jun;17(6):410-6. doi: 10.1016/j.annepidem.2006.10.012.

12. McFarland LV, **Dublin S**. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. *World J Gastroenterol*, 2008 May 7;14(17):2650-61. doi: 10.3748/wjg.14.2650. PMC2709042.
13. Thomas MC, **Dublin S**, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr, Smith NL, Psaty BM, Siscovick DS, Heckbert SR. Blood pressure control and risk of incident atrial fibrillation. *Am J Hypertens*, 2008 Oct;21(10):1111-6. doi: 10.1038/ajh.2008.248. PMC2577029.
14. Heckbert SR, Wiggins KL, Glazer NL, **Dublin S**, Psaty BM, Smith NL, Longstreth Jr WT, Lumley T. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. *Am J Hypertens*, 2009 May;22(5):538-44. doi: 10.1038/ajh.2009.33. PMC2672972.
15. Breitner JCS, Haneuse S, Walker R, **Dublin S**, Crane PK, Gray SL, Larson EB. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. *Neurology*, 2009 Jun 2;72(22):1899-1905. doi: 10.1212/WNL.0b013e3181a18691. PMC2690966.
16. **Dublin S**, Jackson MJ, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case control study. *BMJ*, 2009 Jun 16;338:b2137. doi: 10.1136/bmj.b2137. PMC2697311.
17. Thacker EL, Wiggins KL, Rice KM, Longstreth WT, Bis JC, **Dublin S**, Smith NL, Heckbert SR, Psaty BM. Short term and long term risk of incident ischemic stroke after transient ischemic attack. *Stroke*, 2010 Feb;41(2):239-43. doi: 10.1161/STROKEAHA.109.569707. PMC2818812.
18. **Dublin S**, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. *J Gen Intern Med*, 2010 Aug;25(8):853-8. doi: 10.1007/s11606-010-1340-y. PMC2896589.
19. **Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and histamine-type 2 receptor blockers and risk of pneumonia in older adults: a population-based case-control study. *Pharmacoepidemiol Drug Saf*, 2010 Aug;19(8):792-802. doi: 10.1002/pds.1978. PMC2938739.
20. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, **Dublin S**, Platt R. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. *Pharmacoepidemiol Drug Saf*, 2011 Feb;20(2):138-45. doi: 10.1002/pds.2068. PMC3232183.
21. Gray SL, Walker R, **Dublin S**, Haneuse S, Crane PK, Breitner JCS, Bowen J, McCormick W, Larson EB. Histamine-2 receptor antagonist use and incident dementia in an older cohort. *J Amer Geriatr Soc*, 2011 Feb;59(2):251-7. doi: 10.1111/j.1532-5415.2010.03275.x. PMC3115775.
22. **Dublin S**, Anderson ML, Heckbert SR, Haneuse SJ, Crane PK, Breitner JCS, McCormick W, Bowen JD, Teri L, McCurry SM, Larson EB. Atrial fibrillation and risk of dementia: a prospective cohort study. *J Amer Geriatr Soc*, 2011 Aug;59(8):1369-75. doi: 10.1111/j.1532-5415.2011.03508.x. PMC3289545.
23. **Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, Jackson LA. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. *J Am Geriatr Soc*, 2011 Oct;59(10):1899-907. doi: 10.1111/j.1532-5415.2011.03586.x. PMC3223721.
24. Andrade SE, Davis RL, Cheetham TC, Cooper WO, Li DK, Amini T, Beaton SJ, **Dublin S**, Hammad TA, Pawloski PA, Raebel MA, Smith DH, Staffa JA, Toh S, Dashevski I, Haffnerreffer K, Lane K, Platt R, Scott PE. Medication exposure in pregnancy risk evaluation program. *Matern Child Health J*, 2011 Oct;16(7):1349-54. doi: 10.1007/s10995-011-0902-x. PMC3361624.
25. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, **Dublin S**, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh N, Ray WA, Selby JV. ADHD Medications and Risk of Serious Cardiovascular Events In Young and Middle-Aged Adults. *JAMA* 2011 Dec 28;306(24):2673-83. Epub 2011 Dec 12. PMC3350308.
26. *Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, **Dublin S**. A systematic review of validated methods for identifying atrial fibrillation using administrative data. *Pharmacoepidemiol Drug Saf*, 2012 Jan;21(S1):141-47. doi: 10.1002/pds.2317. PMC3674852.

27. **Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. *Pharmacoepidemiol Drug Saf*, 2012 Nov;21(11):1173-1182. doi: 10.1002/pds.3340. PMC3740964.
28. Bobo WV, Davis RL, Toh SD, Li D-K, Andrade SE, Cheetham TC, Pawloski PA, **Dublin S**, Pinheiro S, Hammad T, Scott PE, Epstein RA, Arbogast PG, Morrow JA, Dudley JA, Lawrence JM, Avalos LA, Cooper WO. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a Medication Exposure in Pregnancy Risk Evaluation Program study. *Paediatr Perinat Epidemiol*, 2012 Nov;26(6):578-588. doi: 10.1111/ppe.12004. PMC3481178.
29. Andrade SE, Scott PE, Davis RL, Li D-K, Getahun DT, Cheetham TC, Raebel MA, Toh S, **Dublin S**, Pawloski PA, Hammad TA, Beaton SJ, Smith DH, Dashevsky I, Haffner K, Cooper WO. Validity of health plan and birth certificate data for pregnancy research. *Pharmacoepidemiol Drug Saf*, 2013 Jan;22(1):7-15. doi: 10.1002/pds.3319. PMC3492503.
30. Thacker EL, McKnight B, Psaty BM, Longstreth WT, **Dublin S**, Jensen PN, Newton KM, Smith NL, Siscovick DS, Heckbert SR. Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation. *J Gen Intern Med*, 2013 Feb;28(2):247-253. doi: 10.1007/s11606-012-2220-4. PMC3614136.
31. Lawrence JM, Andrade SE, Avalos LA, Beaton SJ, Chiu VY, Davis RL, **Dublin S**, Pawloski PA, Raebel MA, Smith DH, Toh S, Wang JQ, Kaplan S, Amini T, Hampp C, Hammad TA, Scott PE, Cheetham TC; for the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) Study Group. Prevalence, trends and patterns of use of antidiabetic medications among pregnant women, 2001-2007. *Obstet Gynecol*, 2013;121:106-114. doi: http://10.1097/AOG.0b013e318278ce86. PMC3811068.
32. Jensen PN, Thacker EL, **Dublin S**, Psaty BM, Heckbert SR. Racial differences in the incidence of and risk factors for atrial fibrillation in older adults: the Cardiovascular Health Study. *J Amer Geriatr Soc*, 2013 Feb;61(2):276-280. doi: 10.1111/jgs.12085. PMC3878638.
33. Li Q, Andrade SE, Cooper WO, Davis RL, **Dublin S**, Hammad TA, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Dashevsky I, Haffner K, Johnson KE, Toh S. Validation of an algorithm to estimate gestational age in electronic health plan databases. *Pharmacoepidemiol Drug Saf*, 2013 May;22(5):524-532. doi: 10.1002/pds.3407. PMC3644383.
34. Avery TR, Kulldorff M, Vilk Y, Lingling L, Cheetham TC, **Dublin S**, Davis RL, Liu L, Herrinton L, Brown JS. Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual. *Pharmacoepidemiol Drug Saf*, 2013;22(5):488-95. doi: 10.1002/pds.3412. PMC3644310.
35. Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, **Dublin S**, Hammad TA, Li D-K, Pawloski PA, Pinheiro SP, Raebel MA, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffner K, Avalos LA, Andrade SE. Prevalence and trends in the use of antipsychotic drugs during pregnancy in the US: a population-based study of 585,615 deliveries. *Arch Women's Mental Health*, 2013;16(2):149-57. doi: 10.1007/s00737-013-0330-6. PMC3715880.
36. Hansen C, Joski P, Freiman HC, Andrade SE, Toh S, **Dublin S**, Cheetham TC, Cooper WO, Pawloski PA, Li D-K, Beaton SJ, Scott PE, Hammad T, Davis RL. Medication in Pregnancy Risk Evaluation Program: the prevalence of asthma medication use during pregnancy. *Matern Child Health J*, 2013 Nov;17(9):1611-21. doi: 10.1007/s10995-012-1173-x. PMC3797257.
37. Avalos LA, Chen H, Yang C, Andrade SE, Cooper WO, Cheetham TC, Davis RL, **Dublin S**, Hammad TA, Kaplan S, Pawloski PA, Raebel MA, Scott PE, Smith DH, Toh S, Li D-K. The prevalence and trends of antiviral medication use during pregnancy in the US: A population-based study of 664,297 deliveries in 2001-2007. *Matern Child Health J*, 2014;18(1):64-72. doi: 10.1007/s10995-013-1234-9. PMC3776000.
38. **Dublin S**, Baldwin E, Walker RL, Christensen LM, Haug PJ, Jackson ML, Nelson JC, Ferraro J, Carrell D, Chapman WW. Natural Language Processing to identify pneumonia from radiology reports. *Pharmacoepidemiol Drug Saf*, 2013 Aug;22(8):834-841. doi: 10.1002/pds.3418. PMC3811072.

39. Johnson KE, Beaton SJ, Andrade SE, Cheetham TC, Scott PE, Hammad TA, Dashevsky I, Cooper WO, Davis RL, Pawloski PA, Raebel MA, Smith DH, Toh S, Li D-K, Haffenreffer K, **Dublin S**. Methods of linking mothers and infants using health plan data for studies of pregnancy outcomes. *Pharmacoepidemiol Drug Saf*, 2013 Jul;22(7):776-786. doi: 10.1002/pds.3443. PMC3707923.
40. Thacker EL, McKnight B, Psaty BM, Longstreth WT, Sitlani CM, **Dublin S**, Arnold AM, Fitzpatrick AL, Gottesman R, Heckbert SR. Atrial fibrillation and cognitive decline: a longitudinal cohort study. *Neurology*, 2013 Jul 9;81(2):119-125. doi: 10.1212/WNL.0b013e31829a33d1. PMC3770176.
41. **Dublin S**, Anderson ML, Heckbert SR, Hubbard RA, Sonnen JA, Crane PK, Montine TJ, Larson EB. Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. *J Gerontol A Biol Sci Med Sci*, 2014 May; 69(5)609-15. doi: 10.1093/gerona/glt141. PMC3991149.
42. Darney BG, Snowden JM, Cheng YW, Jacob L, Nicholson JM, Kaimal A, **Dublin S**, Getahun D, Caughey AB. Elective induction of labor at term compared to expectant management: Maternal and neonatal outcomes. *Obstet Gynecol* 2013;122(4):761-9. doi: 10.1097/AOG.0b013e3182a6a4d0. PMC3905733.
43. **Dublin S**, Johnson KE, Walker RL, Avalos LA, Andrade SE, Beaton SJ, Davis RL, Herrinton LJ, Pawloski PA, Raebel MA, Smith DH, Toh S, Caughey AB. Trends in elective labor induction for six United States health plans, 2001-2007. *J Womens Health (Larchmt)*, 2014 Nov;23(11):904-11. doi: 10.1089/jwh.2014.4779. PMC4235981.
44. Baldwin E, Johnson K, Berthoud H, **Dublin S**. Linking mothers and infants within electronic health records: a comparison of deterministic and probabilistic algorithms. *Pharmacoepidemiol Drug Saf*, 2015;24(1):45-51. doi: 10.1002/pds.3728. Epub 2014 Nov 18.
45. Thacker EL, Jensen PN, Psaty BM, McKnight B, Longstreth WT, **Dublin S**, Sitlani CM, Newton KM, Smith NL, Siscovick DS, Heckbert SR. Use of statins and antihypertensive medications in relation to risk of longstanding persistent atrial fibrillation. *Ann Pharmacother*, 2015;49(4)378-86. doi: 10.1177/1060028014568447. PMC4562688.
46. *Paul KJ, Walker RL, **Dublin S**. Anticholinergic medications and risk of community-acquired pneumonia in the elderly: a population-based case-control study. doi: 10.1111/jgs.13327. *J Am Geriatr Soc*, 2015 Mar;63(3):476-85.
47. Gray SL, Anderson ML, **Dublin S**, Hanlon JT, Hubbard R, Walker R, Yu O, Crane P, Larson EB. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med*, 2015;175(3):401-7. doi: 10.1001/jamainternmed.2014.7663. PMC4358759.
48. **Dublin S**, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Crane PK, Larson EB. Prescription opioids and risk of dementia or cognitive decline: a prospective cohort study. *J Am Geriatr Soc*, 2015;63(8):1519-26. doi: 10.1111/jgs.13562. PMC4776316.
49. LeResche L, Saunders K, **Dublin S**, Thielke S, Merrill JO, Shortreed SM, Campbell C, Von Korff MR. Sex and age differences in global pain status among patients using opioids long-term for chronic non-cancer pain. *J Womens Health (Larchmt)*, 2015 Aug;24(8):629-635. doi: 10.1089/jwh.2015.5222. PMC4545568.
50. Black MH, Zhou H, Sacks DA, **Dublin S**, Lawrence JM, Harrison TN, Reynolds K. Prehypertension prior to or during early pregnancy is associated with increased risk for hypertensive disorders in pregnancy and gestational diabetes. *J Hypertens*, 2015 Sep;33(9):1860-7. doi: 10.1097/HJH.0000000000000646.
51. Bowles EJA, Larson EB, Pong RP, Walker RL, Anderson ML, Yu O, Gray SL, Crane PK, **Dublin S**. Anesthesia exposure and risk of dementia and Alzheimer's disease: a prospective study. doi: 10.1111/jgs.14024. *J Am Geriatr Soc*, 2016 Mar;64(3):602-7. PMC4803643.
52. Floyd JS, Wiggins KL, Sitlani CM, Flory JH, **Dublin S**, Smith NL, Heckbert SR, Psaty BM. Case-control study of second-line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke. *Diabetes Obes Metab*, 2015 Dec;17(12):1194-7. doi: 10.1111/dom.12537. PMC4626290.
53. Wallace ER, Siscovick DS, Sitlani CM, **Dublin S**, Mitchell PH, Odden MC, Hirsch CH, Thielke S, Heckbert SR. Incident atrial fibrillation and disability-free survival in the Cardiovascular Health Study. *J Am Geriatr Soc*, 2016 Apr;64(4):838-43. doi: 10.1111/jgs.14037. PMC4840029.

54. Von Korff M, **Dublin S**, Walker RL, Parchman M, Shortreed SM, Hansen RN, Saunders K. The impact of opioid risk reduction initiatives on high-dose opioid prescribing for chronic opioid therapy patients. *J Pain*, 2016 Jan;17(1):101-10. doi: 10.1016/j.jpain.2015.10.002. PMC4698093.
55. Hansen C, Andrade SE, Freiman H, **Dublin S**, Haffner K, Cooper WO, Cheetham TC, Toh S, Li D-K, Raebel MA, Kuntz JL, Perrin N, Rosales AG, Carter S, Pawloski PA, Maloney EM, Graham DJ, Sahin L, Scott PE, Yap J, Davis RL. Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. *Pharmacoepidemiol Drug Saf*, 2016 Feb;25(2):170-8. doi: 10.1002/pds.3919. PMC4772767.
56. Floyd JS, Wiggins KL, Christiansen M, **Dublin S**, Longstreth WT, Smith NL, McKnight B, Heckbert SR, Weiss NS, Psaty BM. Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke. *Pharmacoepidemiol Drug Saf*, 2016 Feb;25(2):151-60. doi: 10.1002/pds.3914.PMC4732925.
57. Jackson ML, Walker RL, Lee S, Larson EB, **Dublin S**. Predicting two-year risk of developing pneumonia in older adults without dementia. *J Am Geriatr Soc*, 2016 Jul;64(7):1439-47. doi: 10.1111/jgs.14228. PMC4943660.
58. Black MH, Zhou H, Sacks DA, **Dublin S**, Lawrence JM, Harrison TN, Reynolds K. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. *J Hypertens*, 2016 Apr;34(4):728-35. doi: 10.1097/HJH.0000000000000855.
59. Gray SL, **Dublin S**, Yu O, Walker RL, Anderson ML, Hubbard R, Crane PK, Larson EB. Benzodiazepine use and risk of incident dementia or cognitive decline. *BMJ*, 2016 Feb 2;352:i90. doi: 10.1136/bmj.i90. PMC4737849.
60. Pocobelli G, **Dublin S**, Enquobahrie DA, Mueller BA. Birthweight and birthweight for gestational age in relation to risk of hospitalization with primary hypertension in children and young adults. *Matern Child Health J*, 2016 Jul;20(7):1415-23. doi:10.1007/s10995-016-1939-7. PMC4943660.
61. Wallace ER, Siscovick DS, Sitlani C, **Dublin S**, Mitchell P, Robbins J, Fink H, Cauley JA, Buzkova P, Carbone L, Chen Z, Heckbert SR. Incident atrial fibrillation and the risk of fracture in the Cardiovascular Health Study. *Osteoporosis Int*, 2017 Feb;28(2):719-725. doi: 10.1007/s00198-016-3778-1. PMC5782802.
62. Hansen RN, Walker RL, Shortreed SM, **Dublin S**, Saunders K, Ludman EJ, Von Korff M. Impact of an opioid risk reduction initiative on motor vehicle crash risk among chronic opioid therapy patients. *Pharmacoepidemiol Drug Saf*, 2017 Jan;26(1):47-55. doi: 10.1002/pds.4130.
63. Figueroa Gray M, Hsu C, Kiel L, **Dublin S**. It's a very big burden on me: women's experiences using insulin for gestational diabetes. *Matern Child Health J*, 2017;21(8):1678-1685. doi: 10.1007/s10995-017-2261-8.
64. **Dublin S**, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Montine TJ, Crane PK, Sonnen JA, Larson EB. Use of analgesics (opioids and nonsteroidal anti-inflammatory drugs) and dementia-related neuropathologic changes in a community-based autopsy cohort. *J Alzheimers Dis*, 2017; 58(2):435-448. doi: 10.3233/JAD-160374. PMC5594560.
65. Von Korff M, Walker RL, Saunders K, Shortreed SM, Thakral M, Parchman M, Hansen RN, Ludman E, Sherman K, **Dublin S**. Prevalence of prescription opioid use disorder among chronic opioid therapy patients after health plan opioid dose and risk reduction initiatives. *Int J Drug Policy*, 2017;46:90-98. doi: 10.1016/j.drugpo.2017.05.053.
66. Bowles EJA, Walker RL, Anderson ML, **Dublin S**, Crane PK, Larson EB. Risk of Alzheimer's Disease or dementia following a cancer diagnosis. *PLOS One*, 2017 Jun 20;12(6):e0179857. doi: 10.1371/journal.pone.0179857. eCollection 2017. PMC5478144.
67. Gray SL, Walker RL, **Dublin S**, Yu O, Bowles EJA, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk: prospective population-based study. *JAGS*, 2018 Feb;66(2):247-253. doi: 10.1111/jgs.15073. PMC5809315.
68. Lee SJ, Larson EB, **Dublin S**, Walker R, Marcum Z, Barnes D. A cohort study of healthcare utilization in older adults with undiagnosed dementia. *J Gen Intern Med*, 2018 Jan;33(1):13-15. doi: 10.1007/s11606-017-4162-3. PMC5756157.

69. Flanagan ME, Larson EB, Walker RL, Keene CD, Postupna N, Cholerton B, Sonnen JA, **Dublin S**, Crane PK, Montine TJ. Associations between use of specific analgesics and concentrations of amyloid β 42 or paired helical filament- τ in regions of human cerebral cortex. *J Alzheimers Dis*, 2018;61(2) 653-662. doi: 10.3233/JAD0170414. PMC5745256.
70. Thakral M, Walker RL, Saunders K, Shortreed SM, Parchman M, Hansen RN, Ludman E, Sherman KJ, **Dublin S**, Von Korff M. Comparing pain and depressive symptoms of chronic opioid therapy patients receiving dose reduction and risk mitigation initiatives to usual care. *J Pain*, 2018 Jan;19(1):111-120. doi: 10.1016/j.jpain.2017.09.006. PMC5745256.
71. Thakral M, Walker RL, Saunders K, Shortreed SM, **Dublin S**, Parchman M, Hansen RN, Ludman E, Sherman KJ, Von Korff M. Impact of opioid dose reduction initiatives on chronic opioid therapy patients at higher risk for opioid-related adverse outcomes. *Pain Med*, 2018 Dec 1;19(12):2450-2458. doi: 10.1093/pm/pnx293. PMC6294398 [Available on 2019-12-01]
72. *Harding BN, Weiss NS, Walker RL, Larson EB, **Dublin S**. Proton pump inhibitor use and fracture risk in older adults. *Pharmacoepidemiol Drug Saf*, 2018;27(6):596-603. doi: 10.1002/pds.4406. PMC5984154.
73. Hammond CA, Blades NJ, Chaudhry SI, Dodson JA, Longstreth WT Jr, Heckbert SR, Psaty BM, Arnold AM, **Dublin S**, Sitlani CM, Gardin JM, Thielke SM, Nanna MG, Gottesman RF, Newman AB, Thacker EL. Long-term cognitive decline after newly diagnosed heart failure: longitudinal analysis in the Cardiovascular Health Study. *Circ Heart Fail*, 2018 Mar 9;11(3): e004476. doi: 10.1161/circheartfailure.117.004476. PMC6072263.
74. Bayliss EA, Tabano HA, Till TM, Anzuoni K, Tai-Seale M, Allore HG, Ganz DA, **Dublin S**, Gruber-Baldini AL, Adams AL, Mazor KM. Data management for applications of patient reported outcomes. *EGEMS*, 2018 May 10;6(1):5. doi: 10/5334/egems.201. PMC5983068.
75. Sherman KJ, Walker RL, Saunders K, Shortreed SM, Parchman M, Hansen RN, Thakral M, Ludman EJ, **Dublin S**, Von Korff M. Doctor-patient trust among chronic pain patients on chronic opioid therapy after opioid risk reduction initiatives: a survey. *J Am Board Fam Med*, 2018;31(4):578-587. doi: 10.3122/jabfm.2018.04.180021.
76. *Pocobelli G, Yu O, Fuller S, Fraser JR, Wartko, P, Chen L, Newton K, Dimer J, McCulloch D, Warwick S, **Dublin S**. One-step approach to identifying gestational diabetes mellitus: association with perinatal outcomes. *Obstet Gynecol*, 2018;132(4):859-867. doi: 10.1097/AOG.0000000000002780.
77. Gray SL, Anderson ML, Hanlon JT, **Dublin S**, Walker RL, Hubbard RA, Yu O, Montine TJ, Crane PK, Sonnen JA, Keene CD, Larson EB. Exposure to strong anticholinergic medications and dementia-related neuropathology in a community-based autopsy study. *J Alzheimers Dis*, 2018;65(2):607-616. doi: 10.3233/JAD-171174. PMC6154381.
78. Von Korff M, Saunders K, **Dublin S**, Walker RL, Thakral M, Sherman KJ, Ludman EJ, Hansen RN, Parchman M, Shortreed SM. Impact of chronic opioid therapy risk reduction initiatives on opioid overdose. *J Pain*, 2019 Jan;20(1):108-117. doi: 10.1016/j.jpain.2018.08.003.
79. **Dublin S**, Walker RL, Shortreed SM, Ludman EJ, Sherman KJ, Hansen RN, Thakral M, Saunders K, Parchman ML, Von Korff M. Impact of initiatives to reduce prescription opioid risks on medically attended injuries in people using chronic opioid therapy. *Pharmacoepidemiol Drug Saf*, 2019 Jan;28(1):90-96. doi: 10.1002/pds.4678.
80. *Chen L, Pocobelli G, Yu O, Shortreed SM, Osmundson S, Fuller S, Wartko P, McCulloch D, Warwick S, Newton KM, **Dublin S**. Early pregnancy hemoglobin A1c and pregnancy outcomes: a population-based study. *Am J Perinatol*, 2018 Nov 30. doi: 10.1055/s-0038-1675619. PMC6612540. [Available on 2020-05-30]
81. Yaffe K, Barnes DE, Rosenberg D, **Dublin S**, Kaup AR, Ludman EJ, Vittinghoff E, Peltz CB, Renz AD, Adams KJ, Larson EB. Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT): Study Protocol. *J Alzheimers Dis*, 2018 Nov 23. doi: 10.3233/JAD-180634. PMC6639147. [Available on 2020-05-23]

82. *Figueroa Gray M, Hsu C, Kiel L, **Dublin S**. Getting through the day: women's experiences making decisions about anti-nausea medication during pregnancy. *BMC Pregnancy Childbirth*, 2018 Dec 4;18(1):475. doi: 10.1186/s12884-018-2093-6. PMC6280506.
83. Marcum ZA, Walker RL, Jones BL, Ramaprasan A, Gray SL, **Dublin S**, Crane PK, Larson EB. Patterns of antihypertensive and statin adherence prior to dementia: findings from the Adult Changes in Thought study. *BMC Geriatr*, 2019 Feb 14;19(1):41. doi: 10.1186/s12877-019-1058-6. PMC6376744.
84. Scherrer JF, Salas J, Floyd JS, Farr SA, Morley JE, **Dublin S**. Metformin and sulfonylurea use and risk of incident dementia. *Mayo Clinic Proc*, 2019 Aug; 94(8):1444-1456. doi:10.1016/j.mayocp.2019.01.004.
85. Scherrer JF, Morley JE, Salas J, Floyd JS, Farr SA, **Dublin S**. Association between Metformin Initiation and Incident Dementia among African-American and White Veterans Health Affairs Patients. *Ann Fam Med*, 2019 Jul;17(4):352-362. doi: 10.1370/afm.2415.
86. *Wartko PD, Weiss NS, Mueller BA, Enquobahrie D, Chan G, Stephenson-Famy A, **Dublin S**. Antidepressant continuation in pregnancy and risk of gestational diabetes. *Pharmacoepidemiol Drug Saf*, 2019 Jul 12. doi: 10.1002/pds.4799. [Epub ahead of print]
87. Barnes DE, Zhou J, Walker RL, Larson EB, Lee SJ, Boscardin WJ, Marcum ZA, **Dublin S**. Development and validation of eRADAR: a tool using EHR data to detect unrecognized dementia. *JAGS*, 2019 Oct 14; doi: 10.1111/jgs.16182. [Epub ahead of print].
88. Gray SL, Marcum ZA, **Dublin S**, Walker R, Golchin N, Rosenberg DE, Bowles EJ, Crane P, Larson EB. Medications acting on the central nervous system and fall-related injuries in community dwelling older adults: a new user cohort study. *J Gerontol A Biol Sci Med Sci*. 2019 Nov 22. pii: glz270. doi: 10.1093/gerona/glz270. [Epub ahead of print].
89. *Chen L, Shortreed SM, Easterling T, Cheetham TC, Reynolds K, Avalos LA, Kamineni A, Holt V, Neugebauer R, Akosile M, Nance N, Bider-Canfield Z, Walker RL, Badon SE, **Dublin S**. Identifying hypertension in pregnancy using electronic medical records: the importance of blood pressure values. *Pregnancy Hypertension* 2020 Jan;19:112-118. doi: 10.1016/j.preghy.2020.01.001. Epub 2020 Jan 3.
90. *Harding BN, Floyd JS, Scherrer JF, Salas J, Morley JE, Farr SA, **Dublin S**. Methods to identify dementia in the electronic health record: comparing cognitive test scores with dementia algorithms. *Healthcare* 2020 Jun;8(2):100430. doi: 10.1016/j.hjdsi.2020.100430. Epub 2020 May 22.
91. *Wartko PD, Weiss NS, Enquobahrie DA, Chan G, Stephenson-Famy A, Mueller BA, **Dublin S**. Maternal gestational weight gain in relation to antidepressant continuation in pregnancy. *Am J Perinatol* 2020 Jun 30. doi: 10.1055/s-0040-1713652. Online ahead of print.
92. Salas J, Morley JE, Scherrer JF, Floyd JS, Farr SA, Zubatsky M, Barthold D, **Dublin S**. Risk of Incident Dementia following Metformin Initiation compared with Non-initiation or Delay of Antidiabetic Medication Therapy. *Pharmacoepidemiol Drug Saf* 2020 Jun;29(6):623-634. doi: 10.1002/pds.5014. Epub 2020 May 3.
93. Leonard CE, Brensinger CM, Pham Nguyen TP, Horn JR, Chung S, Bilker WB, **Dublin S**, Soprano SE, Dawwas GK, Oslin DW, Wiebe DJ, Hennessy S. Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. *Biomedicine & Pharmacotherapy* 2020;130:110531.
94. Cheetham TC, **Dublin S**, Pocobelli G, Bobb J, Andrade S, Hechter RC, Portugal C, Munis M, Albertson-Junkans L, Salgado G, Wong L, Maarup TJ, Carroll K, Griffin MR, Raebel M, A Smith D, Li D-K, Pawloski PA, Toh S, Taylor L, Hua W, Dinatale M, Ceresa C, Trinidad J, Boudreau DM. Validity of diagnosis and procedure codes for identifying neural tube defects in infants. *Pharmacoepidemiol Drug Saf*. 2020 Nov;29(11):1489-1493. doi: 10.1002/pds.5128. Epub 2020 Sep 15
95. **Dublin S**, Walker RL, Floyd JS, Shortreed SM, Fuller S, Albertson-Junkans LH, Harrington LB, Greenwood-Hickman MA, Green BB, Psaty BM. Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study. *Am J Hypertension* 2020 Oct 13;hpaa168. doi: 10.1093/ajh/hpaa168. Online ahead of print.

96. Badon SE, **Dublin S**, Nance N, Hedderson MM, Neugebauer R, Easterling T, Cheetham TC, Chen L, Holt VL, Avalos LA. Gestational weight gain and adverse pregnancy outcomes by pre-pregnancy BMI category in women with chronic hypertension: a cohort study. *Pregnancy Hypertension*, in press.
97. Wyner Z, **Dublin S**, Albertson-Junkans L, Deval S, Hert S, Herzig-Marx C, Kiel L, Klasnja P, Rao S, Rauch A, Reynolds J, Brown J, Martin D. The FDA MyStudies App: a reusable platform for distributed clinical trials and real world evidence studies. *JAMIA*, in press.
98. Leonard CE, Brensinger CM, Acton AK, Miano TA, Dawwas GK, Horn JR, Chung S, Bilker WB, **Dublin S**, Soprano SE, Nguyen TPP, Manis MM, Oslin DW, Wiebe DJ, Hennessy S. Population-based signals of antidepressant drug interactions associated with unintentional traumatic injury. *Clinical Pharmacology & Therapeutics*, in press.

*First author was a student, resident, postdoctoral fellow or junior faculty member for whom I was the primary mentor.

SUBMITTED

*Chen L, Cheetham TC, Reynolds K, Shortreed SM, Easterling T, Avalos LA, Neugebauer R, Holt VL, Badon SE, Akosile M, Bider-Canfield Z, Nance N, **Dublin S**. Hypertension interruption during pregnancy among women with chronic hypertension.

*Wartko PD, Weiss NS, Enquobahrie DA, Chan G, Stephenson-Famy A, Mueller BA, **Dublin S**. Association of antidepressant continuation in pregnancy and infant birthweight.

EDITORIALS AND COMMENTARIES

Dublin S, Wartko PD, Mangione-Smith R. Studying medication safety in pregnancy: a call for new approaches, resources and collaborations. Invited commentary, *Pediatrics*. [Epub 2020 Jun 8]

Dublin S, Von Korff M. Prescription opioids and infection risk: research and caution needed. Invited editorial, *Annals of Internal Medicine*, 2018 Feb 13. doi: 10.7326/M18-0001. [Epub ahead of print]

TECHNICAL REPORTS

*Jensen PN, **Dublin S**, Johnson K, Floyd J, Heckbert SR. Mini-Sentinel Systematic Evaluation of Health Outcome of Interest Definitions for Studies Using Administrative Data: Atrial Fibrillation Report. Posted June 30, 2011. URL: http://www.mini-sentinel.org/work_products/HealthOutcomes/Mini-Sentinel-HOI-Evidence-Review-Atrial-Fibrillation-Report.pdf

Dublin S, Walker R, Rutter C, Nelson J, Fireman B, Graham D, Psaty B, Setoguchi S, Shoaibi A. Mini-Sentinel Methods: Collecting Supplemental Information via Two-phase Study Designs to Investigate Signals Arising from Medication Safety Surveillance Activities. Posted January 14, 2014. URL: http://www.mini-sentinel.org/work_products/Statistical_Methods/Mini-Sentinel_Methods_Supplemental-Information_Two-Phase-Study-Designs.pdf

Wyner Z, **Dublin S**, Reynolds J, Herzig-Marx C, Deval S, Rao S, Rauch A, Hert S, Chambers C, Brown J, Klasnja P, Kiel L, Albertson-Junkans L, Martin D. The FDA MyStudies App: Patient Centered Outcomes Research Trust Fund Enabler for Distributed Clinical Trials and Real World Evidence Studies. October 10, 2018. URL: https://www.sentinelinitiative.org/sites/default/files/Final_Report-Collection_of_Patient-Provided_Information_Through_a_Mobile_Device_Application.pdf

SELECTED PRESENTATIONS, POSTERS AND ABSTRACTS

ORAL PRESENTATIONS

- Dublin S**, Walker RL, Floyd JS, Shortreed SM, Fuller S, Albertson-Junkans LH, Harrington LB, Greenwood-Hickman MA, Green BB, Psaty BM. Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study. Oral (online) presentation at special web-based session, Specific Treatment-Outcome Association Studies of COVID-19, presented by the International Society for Pharmacoepidemiology, December 1, 2020.
- Dublin S**, Akosile M, Avalos LA, Cheetham TC, Easterling TR, Chen L, Nance N, Bider-Canfield Z, Holt VL, Neugebauer RS, Reynolds K, Badon SE, Shortreed SM. Comparing maternal and neonatal outcomes with use of different antihypertensive medications in pregnancy. Oral presentation, International Conference on Pharmacoepidemiology (online conference), September 2020.
- Dublin S**, Akosile MA, Chen L, Avalos LA, Cheetham TC, Easterling T, Holt VL, Badon SL, Neugebauer RS, Reynolds K, Walker RL, Shortreed SM. Does the type of antihypertensive medication used in pregnancy affect risk of pre-eclampsia? Oral presentation, International Conference on Pharmacoepidemiology, Philadelphia, Pennsylvania, August 26, 2019.
- Barnes DE (presenter), Zhou J, Walker RL, Larson EB, Lee SJ, Boscardin WJ, Marcum Z, **Dublin S**. Development and Validation of the Electronic Health Record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR). Oral presentation, Alzheimer's Association International Conference, Los Angeles, California, July 2019.
- Wartko PD (presenter), Weiss NS, Enquobahrie DA, Chan KCG, Stephenson-Famy A, Mueller BA, **Dublin S**. Validity of maternal weight and gestational weight gain measures from birth certificates. Oral presentation, Society for Epidemiologic Research Annual Meeting; June 19, 2019; Minneapolis, MN.
- Palazzo L (presenter), Figueroa-Gray M, Hsu C, Greenwood-Hickman MA, Barnes D, **Dublin S**. Recognizing risk: New ways to use health data for patient centered dementia care. Society for Applied Anthropology, Portland, Oregon, March 2, 2019.
- Chen L (presenter), Easterling T, Cheetham TC, Reynolds K, Avalos LA, Holt V, Neugebauer S, Shortreed SM, Akosile M, Kamineni A, Walker R, Badon SE, **Dublin S**. Using Blood Pressure Values from Electronic Medical Records to Identify Hypertension During Pregnancy. Oral presentation, 2018 Joint Hypertension Scientific Session, Chicago, Illinois, September 2018.
- Wartko PD (presenter), Weiss N, Enquobahrie DA, Mueller BA, Chan GKC, Stephenson-Famy A, **Dublin S**. Association of antidepressant continuation in pregnancy with maternal gestational weight gain and gestational diabetes. Oral presentation, International Conference on Pharmacoepidemiology, Prague, Czech Republic, August 25, 2018.
- Harding BN (presenter), Scherrer JF, Floyd J, Farr SA, **Dublin S**. Methods to detect dementia in the electronic health record: Comparing cognitive test scores with dementia algorithms. Oral presentation, International Conference on Pharmacoepidemiology and Therapeutic Risk Management Annual Meeting, Prague, Czech Republic, August 26, 2018.
- Dublin S**. Collecting Patient-Reported Data via a Mobile App for Pregnancy Studies. Oral presentation, Teratology Society 58th Annual Meeting, Clearwater, Florida, June 24, 2018.

- Pocobelli G (presenter), Yu O, Fuller S, Fraser J, Wartko P, Chen L, Newton KM, McCulloch D, Warwick S, **Dublin S**. Maternal and neonatal outcomes in relation to adoption of the 1-step approach to identifying gestational diabetes mellitus. Oral presentation, Society for Maternal-Fetal Medicine Annual Meeting, Dallas, Texas, February 2, 2018.
- Dublin S**. Developing a mobile app for studies of medication safety. Oral presentation as part of a symposium entitled, "Listening to the Patient Voice in Pharmacoepidemiological Research: Opportunities for Innovation and Inclusion." International Conference on Pharmacoepidemiology, Montreal, Quebec, Canada, August 29, 2017.
- Dublin S**, Gray SL, Walker RL, Yu O, Aiello Bowles EJ, Anderson, ML, Crane PL, Larson EB. Proton pump inhibitor use and dementia risk. Oral presentation, International Conference on Pharmacoepidemiology, Montreal, Quebec, Canada, August 2017.
- Dublin S**, Von Korff M, Saunders K, Walker RL, Thakral M, Sherman KJ, Ludman E, Hansen RN, Parchman M, Shortreed SM. Impact of risk reduction initiatives on rates of opioid overdose. Oral presentation, International Conference on Pharmacoepidemiology, Montreal, Quebec, Canada, August 2017.
- Gray SL, Anderson ML, **Dublin S** (presenter), Hanlon JT, Hubbard R, Walker RL, Yu O, Crane P, Larson EB. Cumulative Use of Strong Anticholinergic Medications and Incident Dementia. Oral presentation, International Conference on Pharmacoepidemiology, Boston, MA, August 22-26, 2015.
- Gray S, Anderson ML, **Dublin S**, Hanlon J, Yu O, Walker R, Hubbard R, Crane P, Larson E. Anticholinergic medication use and incident dementia. Oral presentation and winner of Best Paper Award, Epidemiology Section, American Geriatrics Society Annual Scientific Meeting, Orlando, Florida, May 2014. *J Am Geriatr Soc* 2014; 62(Suppl. 1): S11.
- Dublin S**, Walker RL, Gray SL, Hubbard R, Anderson ML, Yu O, Crane PK, Larson EB. Use of opioids and risk of dementia in older adults. Oral presentation, International Conference on Pharmacoepidemiology, Montreal, Canada, August 26, 2013. Abstract: *Pharmacoepidemiology and Drug Safety* 2013; 22(Suppl 1): 8. Epublished 7 Oct 2013. DOI: 10.1002/pds.3512.
- Dublin S**, Jackson ML, Marsh T, Setoguchi-Iwata S, Jonsson Funk M, Brookhart MA. New approaches to account for selection bias and confounding by frail health status (accepted symposium; I was the organizer and moderator). International Conference on Pharmacoepidemiology, Montreal, Canada, August 27, 2013.
- Dublin S**, Solti I, Matheny ME, Kors JA, Carrell D. Unlocking the secrets of free text through natural language processing: an introduction for pharmacoepidemiologists (accepted symposium; I was the organizer and moderator). International Conference on Pharmacoepidemiology, Montreal, Canada, August 28, 2013.
- Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Discrepant results in pneumonia studies using solely administrative data compared to medical record review. Oral presentation. International Conference on Pharmacoepidemiology, Chicago, IL, August 15, 2011.
- Dublin S**, Baldwin E, Walker R, Haug P, Carrell D, Chapman W. Accuracy of Natural Language Processing To Identify Pneumonia From Electronic Radiology Reports (oral presentation, plenary session). 16th Annual HMO Research Network Conference, Boston MA, March 24, 2011. Received 2011 Early Career Investigator Award.

Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and histamine type 2 receptor blockers is not associated with pneumonia risk (oral presentation). International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI, August 2009.

Dublin S. Statin use and risk of pneumonia. Invited oral presentation, Young Investigators plenary session. 15th Annual HMO Research Network Conference, Danville, PA, April 29, 2009.

Dublin S. Healthy user bias in studies of vaccine effects. Oral presentation as part of workshop titled, "Selective prescribing, frailty, and healthy-user effects in pharmacoepidemiology." International Conference on Pharmacoepidemiology, Copenhagen, Denmark, August 19, 2008.

POSTER PRESENTATIONS

Carls G, Hansen RN, Pocobelli GS, Eavey J, Akosile MA, Wellman RD, Johnson RL, Bron M, **Dublin S**. Obstructive Sleep Apnea and Risk of Motor Vehicle Accident. [ATS abstract B69]. *Am J Respir Crit Care Med*. 2020;201: A4134. Virtual poster presentation at American Thoracic Society 2020 Virtual Conference, August 5-10, 2020.

Hansen RN, Pocobelli G, Eavey J, Akosile M, Wellman R, Johnson R, Bron M, Carls G, Dublin S. Obstructive Sleep Apnea and Risk of Motor Vehicle Accidents. [Psych Congress abstract]. Poster presented at Psych Congress, September 10-13, 2020, Virtual Meeting.

Wartko PD, Howe AS, Shortreed SM, Mangione-Smith R, **Dublin S**. Trends in anti-nausea medication use in pregnancy in New Zealand, 2006-2016. International Conference on Pharmacoepidemiology (online conference), September 2020.

Badon SE (presenter), **Dublin S**, Nance N, Neugebauer R, Easterling T, Cheetham TC, Chen L, Holt V, Avalos LA. Gestational weight gain and pregnancy outcomes in women with chronic hypertension. Poster presentation, Society for Pediatric and Perinatal Epidemiologic Research Annual Meeting. 2019 Jun 17-18; Minneapolis, MN.

Badon SE (presenter), **Dublin S**, Nance N, Neugebauer R, Easterling T, Cheetham TC, Chen L, Holt V, Avalos LA. Gestational weight gain and pregnancy outcomes in women with chronic hypertension. Poster presentation, Society for Epidemiologic Research Annual Meeting. 2019 Jun 18-21; Minneapolis, MN.

Badon SE (presenter), **Dublin S**, Nance N, Neugebauer R, Easterling T, Cheetham TC, Chen L, Holt V, Avalos LA. Gestational weight gain and pregnancy outcomes in women with chronic hypertension. Poster presentation, 10th International Symposium on Diabetes, Hypertension, Metabolic Syndrome, and Pregnancy. 2019 May 29- Jun 1; Florence, Italy.

Barnes DE (presenter), Zhou J, Walker R, Lee S, Boscardin J, Marcum Z, Larson E, **Dublin S**. Development and Validation of the EHR Risk of Alzheimer's and Dementia Assessment Rule (eRADAR). Gerontological Society of America, Boston, MA, November 15, 2018 (poster presentation).

Scherrer J (presenter), Salas J, **Dublin S**, Floyd J, Farr S, Morley J. Metformin and Risk of Dementia in Patients With Diabetes. Poster presentation, North American Primary Care Research Group Annual Meeting, Chicago, IL, November 2018.

- Chen L (presenter), Shortreed SM, Easterling T, Cheatham TC, Holt V, Avalos LA, Akosile M, Reynolds K, Walker R, Kamineni A, **Dublin S**. Hypertension treatment disruption during pregnancy among women with chronic hypertension. Poster presentation, 2018 Joint Hypertension Scientific Session, Chicago, Illinois, September 2018. (Received an onsite Poster Award.)
- Wartko PD (presenter), **Dublin S**, Kiel L, Ewing J, Albertson-Junkans L, Hsu C, Lapham G. Prevalence and frequency of cannabis use among pregnant women in a large health care system in Washington State. Poster presentation, Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research, Baltimore, Maryland, June 19, 2018.
- Wartko PD (presenter), Weiss N, Enquobahrie DA, Mueller BA, Chan GKC, Stephenson-Famy A, **Dublin S**. Association of antidepressant continuation in pregnancy with maternal gestational weight gain, gestational diabetes and infant birth weight. Poster presentation, Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research, Baltimore, Maryland, June 19, 2018.
- Dublin S**, Walker RL, Bobb JF, Caughey AB, Holt VL, Wing DA, Shi JM, Dukhovny D, Getahun D. Outcomes after non-indicated induction of labor compared to expectant management: an observational study. Poster presentation, Society for Maternal-Fetal Medicine Annual Meeting, Dallas, Texas, February 1, 2018.
- Chen L, Pocobelli G, Yu O, Shortreed S, Osmundson S, Fuller S, Wartko P, Fraser J, McCulloch D, Warwick S, Newton K, **Dublin S**. Early pregnancy hemoglobin A1c values and pregnancy outcomes: a population based analysis. Poster presentation, Society for Maternal-Fetal Medicine Annual Meeting, Dallas, Texas, February 3, 2018.
- Marcum Z, Larson E, Walker R, Golchin N, Rosenberg D, Crane P, **Dublin S**, Gray S. Initiation of Medications Acting on the Central Nervous System (CNS) and Fall-Related Injuries. International Conference on Pharmacoepidemiology, Montreal, Quebec, Canada, August, 2017.
- Harding B, Weiss NS, **Dublin S**. Proton Pump Inhibitor Use and Fracture Risk in Older Adults. Poster presentation, International Conference on Pharmacoepidemiology, Montreal, Quebec, Canada, August 2017.
- Dublin S**, Walker RL, Shortreed SM, Saunders K, Ludman E, Hansen RN, Sherman K, Thakral M, Parchman M, Von Korff. Opioid Risk Reduction Initiatives and Risk of Injuries in People Using Chronic Opioid Therapy. Poster presentation, International Conference on Pharmacoepidemiology, Montreal, Quebec, Canada, August 2017.
- Lee SJ, Larson EB, **Dublin S**, Walker RL, Marcum Z, Barnes DE. Electronic Medical Record (EMR) Predictors of Undiagnosed Dementia. Alzheimer's Association International Conference, London, UK, July 18, 2017 (poster presentation).
- Allen L, Austin TR, Wong SP, Stephenson-Famy A, **Dublin S**. Reducing early-term elective deliveries in Washington State: impact on neonatal intensive care unit admissions for infants born to women aged 35 years and older. Poster presentation, Society for Maternal Fetal Medicine Annual Meeting, Las Vegas, Nevada, January 28, 2017.
- Hansen RN, Walker RL, Shortreed SM, **Dublin S**, Saunders K, Ludman EJ, Von Korff M. Impact of an opioid risk reduction initiative on motor vehicle crash risk among chronic opioid therapy patients. Poster presentation, International Conference on Pharmacoepidemiology, Dublin, Ireland, August 2016.

- Dublin S**, Getahun DT, Walker RL, Holt VL, Bobb J, Darney B, Dukhovny D, Lai J, Pocobelli G, Wing DA, Caughey AB. Validity of electronic health data for pregnancy outcomes. Poster presentation, International Conference on Pharmacoepidemiology, Dublin, Ireland, August 2016.
- Hansen C, Andrade SE, Freiman H, **Dublin S**, Haffner K, Cooper WO, Cheetham TC, Toh D, Li D, Raebel MA, Kuntz, JL, Perrin N, Rosales AG, Carter S, Pawloski PA, Maloney EM, Graham DJ, Sahin L, Scott PE, Yap J, Davis R. Sulfonamide Use during the First Trimester of Pregnancy and Risk of Selected Congenital Anomalies among Live Births. Poster presentation, International Conference on Pharmacoepidemiology, Boston, MA, August 22-26, 2015.
- Paul KJ, Walker RL, **Dublin S**. Anticholinergic Medication Use and Risk of Community-acquired Pneumonia in Older Adults. Poster presentation, International Conference on Pharmacoepidemiology, Boston, MA, August 22-26, 2015.
- Bowles EJA, Larson EB, Pong RP, Walker RL, Anderson M, Yu O, Gray S, Crane PK, **Dublin S**. Anesthesia Exposure and Risk of Dementia and Alzheimer's Disease: A Prospective Study. Poster presentation, International Conference on Pharmacoepidemiology, Boston, MA, August 22-26, 2015.
- Dublin S**, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Crane PK, Larson EB. Prescription opioid use and risk of dementia or cognitive decline (poster; selected for Best Poster competition.) 20th Annual HMO Research Network Conference, Phoenix, AZ, April 1, 2014.
- Toh D, Li Q, Cheetham C, Cooper WO, Davis RL, Dublin S, Hammad T, Li D, Pawloski P, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffner K, Avalos LA, Andrade SE. Prevalence and Trends in the Use of Antipsychotics during Pregnancy in the U.S., 2001-2007. International Conference on Pharmacoepidemiology, Barcelona, Spain, August 23-26, 2012.
- Bobo WV, Davis RL, Toh SD, Li D, Andrade SE, Cheetham TC, Pawloski P, **Dublin S**, Pinheiro S, Hammad T, Scott PE, Epstein RA, Arbogast PG, Morrow JA, Dudley JA, Lawrence JM, Avalos LA, Cooper WO. Antiepileptic Drug Use among Pregnant Women in the U.S., 2001-2007: A MEPREP Study. International Conference on Pharmacoepidemiology, Barcelona, Spain, August 23-26, 2012.
- Dublin S**, Johnson K, Beaton S, Cheetham TC, Scott PE, Toh SD, Pawloski P, Raebel M, Smith DH, Hammad TA, Andrade SE. Methods for Linking Mothers and Infants within Health Plans for Studies of Medication Safety in Pregnancy. International Conference on Pharmacoepidemiology, Barcelona, Spain, August 23-26, 2012.
- Li Q, Andrade SE, Cooper WO, Davis RL, **Dublin S**, Hammad T, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Dashevsky I, Haffner K, Johnson KE, Toh SD. Validating a Gestational Length Algorithm Based on Administrative Health Plan Data. International Conference on Pharmacoepidemiology, Barcelona, Spain, August 23-26, 2012.
- Dublin S**, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of Angiotensin-Converting Enzyme Inhibitors Is Not Associated with Decreased Pneumonia Risk. International Conference on Pharmacoepidemiology, Chicago, IL, August 14-17, 2011.
- Kay N (presenter), Lauper J, Sabourin K, **Dublin S**. Lower Risk of Adverse Delivery Outcomes with Non-indicated Induction of Labor. Joint Conference on Health: Innovation and Collaboration in Times of Change. Yakima, WA, October 11-12, 2010.

Avery TR, Vilck Y, Kulldorff M, Li L, Cheetham TC, **Dublin S**, Hsu J, Davis RL, Liu L, Platt R, Brown JS. Prospective Active Surveillance for Medication Safety in Population-Based Health Networks: A Pilot Study. International Conference on Pharmacoepidemiology, Brighton, UK, August 19-22, 2010.

Andrade S, Scott P, Cheetham C, Cooper W, Davis R, Li DK, **Dublin S**, Pawloski P, Raebel M, Toh D. Medication Exposure in Pregnancy Risk Evaluation Program. International Conference on Pharmacoepidemiology, Brighton, UK, August 19-22, 2010.

Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, Jackson LA. Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults. International Conference on Pharmacoepidemiology, Brighton, UK, August 19-22, 2010.

Dublin S, Anderson ML, Heckbert SR, Haneuse SJ, Crane PK, Breitner JCS, McCormick W, Bowen JD, Teri L, McCurry SM, Larson EB. Atrial fibrillation and risk of incident dementia or Alzheimer's disease (poster). American Geriatrics Society Annual Scientific Meeting, Orlando, FL, May 12-15, 2010. *Journal of the American Geriatrics Society* 2010; 58:S122 (Abstract B135). Selected for Presidential Poster Session; received Outstanding Poster Award.

Dublin S, Li T, Gray SL, Nelson JC, Weiss NS, Larson EB. Factors associated with suboptimal benzodiazepine use in older adults (poster presentation). International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI, August 2009.

Moore K, Andrade S, Cassidy-Bushrow A, **Dublin S**, Greenlee R, Nakasato C, Platt R, Raebel M, Rolnick C, Smith D, Brown J. Variation in ICD-9 diagnosis coding within and across health systems (poster). International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting, Orlando, FL, May 16-20, 2009.

Li T, **Dublin S**, Gray SL, Nelson JC, Weiss NS, Larson EB. Factors associated with suboptimal benzodiazepine use in an older US cohort, 2004-2006. Poster presentation, American Geriatrics Society Annual Scientific Meeting, Chicago, IL, April 29-May 2, 2009. *Journal of the American Geriatrics Society* 2009; 57:S43-44.

INVITED ORAL PRESENTATIONS

Dublin S. Studying Medications and COVID-19 Outcomes Using Electronic Health Data. Invited seminar (given remotely) for the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, January 14, 2020.

Dublin S. Evaluation of Kaiser Permanente Washington's gestational diabetes screening change. "Bright Spots" plenary session, Kaiser Permanente Center for Effectiveness and Safety Research Annual Meeting, Seattle, WA, May 22, 2019.

Dublin S and Pocobelli G. Perinatal outcomes associated with the one-step approach to identifying gestational diabetes. University of Washington Epidemiology Department Seminar, Seattle, WA, January 29, 2019.

Dublin S and Pocobelli G. A Learning Health System story: perinatal outcomes associated with a major change in gestational diabetes screening. NIH Collaboratory Grand Rounds Webinar and accompanying podcast, January 25, 2019. Available at <http://rethinkingclinicaltrials.org/grand-rounds-hub/>

Dublin S, Pocobelli G, Yu O, Fuller S, Warwick S. Maternal and neonatal outcomes after a change in approach to diagnosing gestational diabetes. Scientific seminar, Kaiser Permanente Washington Health Research Institute, November 13, 2018.

Early Detection of Dementia: Clues in the EMR (Electronic Medical Record). Webinar presented as part of the Healthcare Systems Research Network-Older Americans Independence Centers AGING Initiative, June 29, 2017.

Studying Pregnancy Outcomes with Electronic Medical Records Data. Invited talk, 2nd Seattle Symposium on Health Care Data Analytics. Seattle, Washington, October 24, 2016.

Studying Pregnancy Outcomes Using Electronic Health Data. Invited talk, National Institute of Child Health and Human Development/Health Systems Partnerships: New Approaches to Advancing Maternal, Child and Rehabilitation Research. National Institute of Child Health and Human Development, Bethesda, Maryland, May 23, 2016.

Studying Pregnancy Outcomes Using Electronic Health Data. Invited seminar, Group Health Research Institute, Seattle, Washington, May 10, 2016.

Engaging Stakeholders in Your Research. Junior Investigator Workshop, Healthcare Systems Research Network annual meeting, April 14, 2016. Role: session organizer and panelist.

Studying Pregnancy Outcomes Using Electronic Health Data. Invited seminar, Epidemiology Department, University of Washington, Seattle, Washington, March 29, 2016.

Leading a Research Team. Presentation to the University of Washington T32 training program on Reproductive, Perinatal and Pediatric Epidemiology, Seattle, Washington, January 8, 2016.

Leadership Development: Key Skills for Leading a Research Team. Presentation to the University of Washington T32 training program on Reproductive, Perinatal and Pediatric Epidemiology, Seattle, Washington, November 13, 2015.

Study Populations: Internal and External Validity and Generalizability. Lecture, Epi 101 course for Group Health Research Institute staff, October 19, 2015.

Speaker and panelist, “Valid Use of Big Data for Pediatric and Perinatal Epidemiology” (plenary session). Society for Pediatric and Perinatal Epidemiologic Research annual meeting, Denver, CO, June 15, 2015.

Two-Phase Study Designs to Improve Efficiency of New Data Collection. FDA Public Workshop: Addressing Inadequate Information on Important Health Factors in Pharmacoepidemiology Studies Relying on Healthcare Databases. Silver Springs, MD, May 4, 2015.

Building Relationships with Funders. New Investigator Career Development Session, HMO Research Network annual meeting, March 11, 2015. Role: session co-organizer and panelist.

Pregnancy Research using Electronic Medical Records. University of California, San Diego Division of Teratology and Dysmorphology's Joint Stats/Epi Methods Seminar, San Diego, CA, November 25, 2014.

Studying Elective Induction Outcomes using Health Plan Data and Electronic Medical Records. Presentation to the University of Washington T32 training program on Reproductive, Perinatal and

Pediatric Epidemiology, Seattle, Washington, November 14, 2014.

Pregnancy Research using Electronic Medical Records. Center for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden, August 22, 2014.

Birth Certificate Linkage: The Good, the Bad and the Unruly. Presentation to HMO Research Network Virtual Data Warehouse Improvement Group, Burlingame, CA, April 18, 2013.

Accounting for Bias in Medication Safety Studies that use Real-World Healthcare Data. Guest lecture to the Introduction to Pharmacoepidemiology class, University of North Carolina, Chapel Hill, NC, February 26, 2013.

Research Opportunities in Integrated Healthcare Delivery Systems. Invited seminar, University of North Carolina Department of Epidemiology, Chapel Hill, NC, February 26, 2013.

Accounting for Bias in Medication Safety Studies that use Real-World Healthcare Data. Invited seminar, Center for Pharmacoepidemiology Research and Training, University of Pennsylvania, January 31, 2013.

Statins and Infection: Miracle or Myth? Grand Rounds, University of Washington Division of Gerontology and Geriatric Medicine, January 18, 2013.

Accounting for Bias in Medication Safety Studies that Use Electronic Healthcare Data. Scientific seminar at Group Health Research Institute, December 11, 2012.

High-Risk Medications in the Elderly. Continuing Medical Education presentation to Group Health's Nursing Home Services division, Seattle, WA, June 7, 2012.

Studying Drug Safety in the Real World: New Data, Expanding Opportunities. Presentation to Medical Scientist Training Program (MD/PhD students), University of Washington, Seattle, WA, September 15, 2011.

Atrial Fibrillation: New Risk Factors and Outcomes. Continuing Medical Education presentation to Group Health's Nursing Home Services division, Seattle, WA, August 4, 2011.

NATIONAL AND INTERNATIONAL RESPONSIBILITIES

Member of the Steering Committee, Innovation in Medical Evidence Development and Surveillance (IMEDS), Reagan-Udall Foundation for the FDA, March 2020-present.

Planning Committee, 2021 International Conference on Pharmacoepidemiology

Co-Chair, Newcomer Track, 2021 International Conference on Pharmacoepidemiology

Planning Committee, 2020 International Conference on Pharmacoepidemiology

Abstract reviewer for Newcomer Track, 2020 International Conference on Pharmacoepidemiology

Planning Committee, 2019 International Conference on Pharmacoepidemiology

Abstract reviewer, International Conference on Pharmacoepidemiology, yearly from 2009-present

Member, Physician Engagement Council, Society for General Internal Medicine Improving Wisely project focused on improving the quality of prescribing by reducing polypharmacy and high risk prescribing in older adults, 2018

Letter of Intent reviewer, HMO Research Network-Older Adults Independence Centers AGING Network pilot project applications, February 2017

External reviewer for PhD dissertation on influenza infection and pregnancy outcomes, McGill University, December 2015

Ad hoc grant reviewer, career development award, UK Medical Research Council, September 2015
Grant reviewer, pilot grant submissions, HMO Research Network-Older Adults Independence Centers
AGING Research Network pilot projects, February 2015
Abstract reviewer, American Geriatrics Society annual meeting, 2015
Abstract reviewer, HMO Research Network Annual Meeting, 2015
Invited faculty, Society for Epidemiologic Research Student Workshop, Seattle, WA, June 2014
Member, Early Career Investigator Award selection committee, HMO Research Network Annual
Meeting, January 2013
Abstract reviewer and session moderator, HMO Research Network Annual Meeting, 2012
Conference co-organizer, International Workshop on Pharmacoepidemiology and Biostatistics for visiting
Chinese researchers and leaders in Traditional Chinese Medicine, Seattle, Washington, December 2-
4, 2011
Planning Committee, Beeson Scholars Annual Meeting, 2011
Independent Safety Monitor for randomized clinical trials at Group Health, Vaccine Therapeutics
Efficacy Unit, 2008-2018
Member, HMO Research Network Virtual Data Warehouse Pharmacy Working Group, 2008-2012

LOCAL RESPONSIBILITIES

Member, Promotions Committee, Kaiser Permanente Washington Health Research Institute, January
2020-present
Founder and leader, Kaiser Permanente Washington Health Research Institute Pharmacoepidemiology
and Therapeutics Methods Interest Group, 2009-present
Member, Morale Award Selection Committee, Kaiser Permanente Washington Health Research Institute,
2016- present
Member, Gestational Diabetes Guideline Review Team, Kaiser Permanente Washington, December
2017-Spring 2018
Chair, Evaluation Committee for potential new faculty hire, Group Health Research Institute, Fall 2016
Member, Birnbaum Award Selection Committee, Group Health Research Institute, 2016
Member, Faculty Search Committee, Group Health Research Institute, 2014
Strategic Planning and Development Steering Committee, Group Health Research Institute, Seattle, WA,
July 2011-January 2012
Clinician-Scientist Task Force, Group Health Research Institute, Seattle, WA, 2009
New Investigator Orientation Working Group, Group Health Research Institute, Seattle, WA, 2009
Member, Diabetes Screening Guideline Development Group, Group Health, Seattle, WA, 2008

TEACHING

Masters Committees

Chair, Master's thesis committee, Barbara Harding, MPH in Epidemiology, University of Washington.
"Proton Pump Inhibitor Use and Risk of Fracture." Completed June 2016.

Chair, Master's thesis committee, Noa Kay, MPH in Epidemiology, University of Washington. "Adverse
maternal and neonatal delivery outcomes associated with non-indicated labor induction at 39 weeks
gestation." Completed June 2011.

Member, Master's thesis committee, Paul Jensen, MPH in Epidemiology, University of Washington.
"Racial differences in the Incidence of and Risk Factors for Atrial Fibrillation in Older Adults: The
Cardiovascular Health Study." Completed December 2011.

Doctoral Committees

Chair, Dissertation committee, Paige Wartko, PhD in Epidemiology, University of Washington.
“Antidepressant use in pregnancy and metabolic outcomes.” Completed August 2018.

Member, Dissertation committee, Erin Wallace, PhD in Epidemiology, University of Washington. “Atrial Fibrillation and Disability-Free Survival, Functional Decline and the Risk of Hip and Forearm Fracture in the Cardiovascular Health Study.” Completed December 2013.

Other teaching and precepting

Invited lecture, University of Washington School of Public Health. EPI 515, Advanced Epidemiologic Methods I. “Use of Electronic Health Data for Research.” November 2, 2020.

Invited lecture, University of Washington School of Public Health. EPI 515, Advanced Epidemiologic Methods I. “Studying COVID-19 Using Electronic Health Data.” November 9, 2020.

Invited lecture, University of Washington School of Public Health. EPI 515, Advanced Epidemiologic Methods I. “Use of Electronic Health Data for Research.” November 18, 2019.

Led a discussion of two articles about methods for screening for gestational diabetes, University of Washington School of Public Health. EPI 591, Current Literature in Epidemiology. May 23, 2019.

Invited lecture, University of Washington School of Public Health. EPI 515, Advanced Epidemiologic Methods I. “Use of Electronic Health Data for Research.” October 29, 2018.

Invited lecture, University of Washington School of Public Health. EPI 533, Pharmacopidemiology. “Studying Medication Safety in Pregnancy.” May 2, 2016; May 4, 2018; and May 18, 2020.

Invited lecture, University of Washington School of Public Health. EPI 515, Advanced Epidemiologic Methods I. “Use of Electronic Health Data for Research.” October 30, 2017.

Invited lecture, University of Washington School of Public Health. EPI 528, Advanced Epidemiologic Methods I. “Use of Electronic Health Data for Research.” November 7, 2016.

Invited lecture, University of Washington School of Public Health. EPI 542, Clinical Epidemiology. “Can Statins Prevent or Treat Infection?” May 25, 2016 and also May 17, 2017.

Invited lecture, University of Washington School of Public Health. EPI 592A, Maternal and Child Health Seminar. “Mentorship.” October 17, 2016.

Small group preceptor, University of Washington School of Public Health. EPI 514, Application of Epidemiologic Methods, Spring quarters of 2010 and 2012-2016. Precepted small group of graduate students analyzing Washington State birth certificate and linked hospital discharge data.

Invited lecture, University of Washington School of Public Health. EPI 542, Clinical Epidemiology. “Can Statins Prevent or Treat Infection?” May 27, 2015.

Invited lecture, University of Washington School of Public Health. EPI 533, Pharmacopidemiology. “Medication Safety in Pregnancy.” May 14, 2014.

Invited lecture, University of Washington School of Public Health. EPI 533, Pharmacopidemiology. "Healthy user bias in observational studies of vaccine & medication effects: the limits of adjustment." April 18, 2012.

Practicum supervisor, MPH practicum, Paul Jensen, 6/2010-2/2011, University of Washington. Project: systematic review for the Food and Drug Administration examining accuracy of algorithms using electronic health data to identify atrial fibrillation (for Mini-Sentinel.)

Invited lecture, University of Washington School of Public Health and Community Medicine. EPI 533, Pharmacopidemiology. "Healthy user bias in observational studies of vaccine & medication effects: the limits of adjustment." May 10, 2010.

Invited session leader, University of Washington School of Public Health and Community Medicine. EPI 591A, Epidemiology Journal Club. "Acid-suppressing medications and risk of hospital-acquired pneumonia." October 22, 2009.

University of Washington School of Medicine, Seattle, WA

2011	Problem-Based Learning (small group co-leader)	10 students, 16 contact hrs
2010	Problem-Based Learning (small group co-leader)	10 students, 16 contact hrs
2008	Problem-Based Learning (substitute group leader)	10 students, 6 contact hrs
2007	Problem-Based Learning (substitute group leader)	10 students, 10 contact hrs
2006	Problem-Based Learning (small group leader)	10 students, 30 contact hrs
2005	Problem-Based Learning (small group leader)	10 students, 30 contact hrs
2001	Introduction to Clinical Medicine	6 students; 6 contact hrs
	Taught physical exam skills to first-year medical students.	
1998 & 1999	Epidemiology (small group discussion leader)	10 students; 6 contact hrs
1998	Tutor, Epidemiology	3-50 students; ~12-15 hrs
	Led weekly reviews for first-year medical students & review sessions for USMLE I-II.	
1996-1998	T.A., Medicine, Health & Society	150 students; 30 hrs.; 3 yrs
	Participated in development of curriculum in health policy & economics for medical students; led small group discussion sessions.	
1994	T.A., Anatomy & Embryology	100 students; 70 contact hours

Oregon Health & Science University, Portland, OR

2002-03	Assisted with epidemiology course for physician assistant students; led journal clubs. Lectured to MPH students and Preventive Medicine students on pharmacoepidemiology and epidemiologic methods.	
---------	--	--

Kaplan Educational Centers, New York, NY and Seattle, WA

1996-1999	Seattle head MCAT instructor, training and supervising 6 other instructors	
1996	National MCAT organic chemistry coordinator	
1994-2000	Seattle MCAT instructor	

PROFESSIONAL CERTIFICATION AND LICENSING

ABIM certification in Internal Medicine, 2004-present. Successful recertification in 12/2014.
Washington State medical license, 2001-present

CLINICAL RESPONSIBILITIES

Clinical practice: 1 day per week in primary care, Kaiser Permanente Washington Federal Way clinic.

OTHER PROFESSIONAL INVOLVEMENT

Peer reviewer, *JAMA*, *Annals of Internal Medicine*, *BMJ*, *Archives of Internal Medicine*, *Journal of General Internal Medicine*, *European Journal of Internal Medicine*, *Journal of Internal Medicine*, *Clinical Infectious Diseases*, *Pediatrics*, and *Pharmacoepidemiology and Drug Safety*

- Named as a top reviewer (in top 10% by review quality) by *Annals of Internal Medicine* in 2008, 2009, 2010, 2011, 2013, 2014 and 2016; as a distinguished reviewer by *Pharmacoepidemiology and Drug Safety* in 2010, 2011, 2013, 2015 and 2018; and as a distinguished reviewer by *JGIM* in 2009.

Associate council member, Society of General Internal Medicine Northwest Region, 2004-2007

- Developed and organized new session, Fellows' Work-in-Progress, highlighting work of Northwest region fellows and matching them with regional mentors

Lecturer on study skills and test-taking skills, Office of Multicultural Affairs, UW School of Medicine

- African American Mentorship Network Retreat, January 2005
- Pre-matriculation program, July 2005 and July 2006
- Pre-medical/pre-dental summer program, July 2005

Member, International Society for Pharmacoepidemiology, 2007-present

Student member, Curriculum Committee, University of Washington School of Medicine, 1993-2001